Across TCGA pan-cancer cohorts, MIR627 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated MIR627 data layer.
The strongest signal is observed in thyroid carcinoma (THCA), where higher MIR627 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MIR627 expression acts as an unfavorable survival marker, although some lineages such as STAD and ESCA show a favorable association.
THCA, KIRP, and READ are the cancer types where MIR627 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.